Drug development is a complex, intricate and multilayered process. The question pharma needs to evaluate is: Is it helping or further complicating the development process if multiple siloed technologies are being adopted and then manually stitched together?
When the team feels it’s “still working,” it’s important to identify new technology solutions with founders and developers who have experience with the legacy system. Often, their modern solution offers better efficiency and other benefits driven by their experience. Understand the potential efficiencies, work together to develop metrics from those claims and put milestones in place to prove them.
The mission of clinical development is to shorten the window between an investigational new drug application and regulatory approval, so why is it the technological black hole of pharma?
Donna Conory, MS, founder and CEO of SciMar ONE, has been accepted into Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs, and technology executives.